Jingxin Qiao

Jingxin Qiao

Auto-generated profile, based on publicly available information

Jingxin Qiao

State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Science
Verified
Journal Article
Open access
PDF file
JQJingxin Qiao
Jingxin Qiao
YLYue-Shan Li
Yue-Shan Li
RZRui Zeng
Rui Zeng
FLFeng-Liang Liu
Feng-Liang Liu
RLRong-Hua Luo
Rong-Hua Luo
SYShengyong Yang
Shengyong Yang
Targeting the SARS-CoV-2 main protease: Vaccines are an important tool in the fight against COVID-19, but developing antiviral drugs is also a high priority, especially with the rise of variants that may partially evade vaccines. The viral protein main protease is required for cleaving precursor polyproteins into functional viral proteins. This essential function makes it a key drug target. Qiao et al. designed 32 inhibitors based on either boceprevir or telaprevir, both of which are protease inhibitors approved to treat hepatitis C virus. Six compounds protected cells from viral infection with high potency, and two of these were selected for in vivo studies based on pharmokinetic experiments. Both showed strong antiviral activity in a mouse model. Science , this issue p. 1374